Gilead grows fibrosis pipeline with Scholar Rock deal

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to

Read the full 268 word article

User Sign In